/
LAB
$0.75+$0.01 (+1.80%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$287.4M
391M shares
52-week range
$0.70 – $1.72
4% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
2.25%
Moderate
Price (6 mo)
Loading chart…
Change$-3.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.0M | $117.2M | $138.1M | $130.6M | $97.9M | $106.3M | $174.4M | $85.3M |
| Cost of revenue | $51.3M | $53.0M | $54.8M | $61.2M | $60.9M | $55.9M | $90.2M | $42.8M |
| Gross profit | $61.6M | $64.3M | $83.3M | $69.4M | $37.1M | $50.5M | $84.3M | $42.5M |
| Gross margin | 54.6% | 54.8% | 60.3% | 53.1% | 37.8% | 47.4% | 48.3% | 49.9% |
| R&D | $30.0M | $31.6M | $36.5M | $37.9M | $37.4M | $25.9M | $62.4M | $26.0M |
| Operating income | −$48.2M | −$51.8M | −$51.0M | −$67.5M | −$116.2M | −$76.6M | −$175.2M | −$93.3M |
| EBITDA | −$31.0M | −$46.6M | −$34.6M | −$44.3M | −$173.6M | −$54.5M | −$118.1M | −$89.7M |
| Net income | −$59.0M | −$64.8M | −$53.0M | −$59.2M | −$190.1M | −$74.7M | −$138.9M | −$74.9M |
| Net margin | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -79.6% | -87.8% |
| EPS (diluted) | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 | -0.20 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $82M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2027 | $84M | $-0.09 | $-0.09–$-0.09 | 1 |
| 2028 | $88M | $-0.08 | $-0.08–$-0.08 | 1 |
| 2029 | $89M | $-0.15 | $-0.15–$-0.15 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Standard BioTools Inc. Common Stock
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
www.standardbio.com- Employees
- 389
- IPO / List date
- Feb 10, 2011
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds LAB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 201,000 | $387.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LAB yet.
